Your browser doesn't support javascript.
loading
A Phase 1 clinical trial of a DNA vaccine for Venezuelan equine encephalitis delivered by intramuscular or intradermal electroporation.
Hannaman, Drew; Dupuy, Lesley C; Ellefsen, Barry; Schmaljohn, Connie S.
Afiliação
  • Hannaman D; Ichor Medical Systems, Inc., San Diego, CA, USA.
  • Dupuy LC; United States Army Medical Research Institute of Infectious Diseases, Fort Detrick, MD, USA.
  • Ellefsen B; Ichor Medical Systems, Inc., San Diego, CA, USA.
  • Schmaljohn CS; United States Army Medical Research Institute of Infectious Diseases, Fort Detrick, MD, USA. Electronic address: connie.s.schmaljohn.civ@mail.mil.
Vaccine ; 34(31): 3607-12, 2016 06 30.
Article em En | MEDLINE | ID: mdl-27206386
ABSTRACT
Venezuelan equine encephalitis virus (VEEV), a mosquito-borne alphavirus, causes periodic epizootics in equines and is a recognized biological defense threat for humans. There are currently no FDA-licensed vaccines against VEEV. We developed a candidate DNA vaccine expressing the E3-E2-6K-E1 genes of VEEV (pWRG/VEE) and performed a Phase 1 clinical study to assess the vaccine's safety, reactogenicity, tolerability, and immunogenicity when administered by intramuscular (IM) or intradermal (ID) electroporation (EP) using the Ichor Medical Systems TriGrid™ Delivery System. Subjects in IM-EP groups received 0.5mg (N=8) or 2.0mg (N=9) of pWRG/VEE or a saline placebo (N=4) in a 1.0ml injection. Subjects in ID-EP groups received 0.08mg (N=8) or 0.3mg (N=8) of DNA or a saline placebo (N=4) in a 0.15ml injection. Subjects were monitored for a total period of 360 days. No vaccine- or device-related serious adverse events were reported. Based on the results of a subject questionnaire, the IM- and ID-EP procedures were both considered to be generally acceptable for prophylactic vaccine administration, with the acute tolerability of ID EP delivery judged to be greater than that of IM-EP delivery. All subjects (100%) in the high and low dose IM-EP groups developed detectable VEEV-neutralizing antibodies after two or three administrations of pWRG/VEE, respectively. VEEV-neutralizing antibody responses were detected in seven of eight subjects (87.5%) in the high dose and five of eight subjects (62.5%) in the low dose ID-EP groups after three vaccine administrations. There was a correlation between the DNA dose and the magnitude of the resulting VEEV-neutralizing antibody responses for both IM and ID EP delivery. These results indicate that pWRG/VEE delivered by either IM- or ID-EP is safe, tolerable, and immunogenic in humans at the evaluated dose levels. Clinicaltrials.gov registry number NCT01984983.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Vacinas Virais / Vacinas de DNA / Encefalomielite Equina Venezuelana Tipo de estudo: Clinical_trials Limite: Adolescent / Adult / Female / Humans / Male / Middle aged País/Região como assunto: America do sul / Venezuela Idioma: En Revista: Vaccine Ano de publicação: 2016 Tipo de documento: Article País de afiliação: Estados Unidos

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Vacinas Virais / Vacinas de DNA / Encefalomielite Equina Venezuelana Tipo de estudo: Clinical_trials Limite: Adolescent / Adult / Female / Humans / Male / Middle aged País/Região como assunto: America do sul / Venezuela Idioma: En Revista: Vaccine Ano de publicação: 2016 Tipo de documento: Article País de afiliação: Estados Unidos